These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 3134813)
1. Discrepant changes in plasminogen by two different assays in patients receiving streptokinase. Hysell DC; Smith MR; Brewster PS; Fraker TD Am J Clin Pathol; 1988 Aug; 90(2):200-5. PubMed ID: 3134813 [TBL] [Abstract][Full Text] [Related]
2. Enzymatic and immunochemical determination of plasminogen and plasmin in different physiological and pathological states. Mannucci PM; Stabilini R; Bragotti R; Marasini B; Agostoni A J Clin Pathol; 1971 Apr; 24(3):228-33. PubMed ID: 4252395 [TBL] [Abstract][Full Text] [Related]
3. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study. Monassier JP; Hanssen M Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540 [TBL] [Abstract][Full Text] [Related]
4. High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation. Mentzer RL; Budzynski AZ; Sherry S Am J Cardiol; 1986 Jun; 57(15):1220-6. PubMed ID: 3717017 [TBL] [Abstract][Full Text] [Related]
5. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
7. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987 [TBL] [Abstract][Full Text] [Related]
8. Fibrinolytic treatment by infusion of streptokinase-plasminogen-complex (activator): laboratory effects. Martin H; Auel H; Riedel C Behring Inst Mitt; 1986 Feb; (79):263-71. PubMed ID: 2424424 [TBL] [Abstract][Full Text] [Related]
9. Histidine-rich glycoprotein and changes in the components of the fibrinolytic system after streptokinase therapy in patients with pulmonary thromboembolism. Goodnough LT; Saito H; Bell WR; Heimburger N Am J Hematol; 1985 Jul; 19(3):245-53. PubMed ID: 4014225 [TBL] [Abstract][Full Text] [Related]
10. Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Samama M; Conard J; Verdy E; van Dreden P; Nguyen G; Combrisson A; Acar J Drugs; 1987; 33 Suppl 3():268-74. PubMed ID: 3315605 [TBL] [Abstract][Full Text] [Related]
11. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis. Collen D; Lijnen HR; Vanderschueren S Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814 [TBL] [Abstract][Full Text] [Related]
12. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction. Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862 [TBL] [Abstract][Full Text] [Related]
13. Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinase antibody. Lew AS; Neer T; Rodriguez L; Geft IL; Shah PK; Ganz W J Am Coll Cardiol; 1984 Jul; 4(1):183-5. PubMed ID: 6736447 [TBL] [Abstract][Full Text] [Related]
14. Streptokinase and reduced plasma viscosity: a second benefit. Moriarty AJ; Hughes R; Nelson SD; Balnave K Eur J Haematol; 1988 Jul; 41(1):25-36. PubMed ID: 3402584 [TBL] [Abstract][Full Text] [Related]
15. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination. Noll G; Lämmle B; Duckert F Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441 [TBL] [Abstract][Full Text] [Related]